Overview of Votrex Retard

Quick Facts

Property	Description
Active ingredient	Diclofenac sodium
Form	Prolonged-release tablet (Retard formulation)
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose	Relief from pain and inflammation
Origin	Synthetic (Phenylacetic acid derivative)

What is Votrex Retard and Its Pharmacological Identity?

Votrex Retard is a single-component, synthetic medicine containing the active substance Diclofenac sodium. It is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a group of agents clinically recognized for their capacity to manage both pain and inflammation.

The active substance, Diclofenac, is a chemical derivative of phenylacetic acid. This pharmacological structure dictates its function as a powerful analgesic (pain-relieving) and anti-inflammatory agent. Diclofenac is recognized as one of the most widely used anti-inflammatory compounds globally. This indicates that the medicine is a foundational tool for generally managing painful inflammatory conditions, such as discomfort associated with musculoskeletal issues.

Votrex Retard: What is the Prolonged-Release Form?

Votrex Retard is administered orally as a prolonged-release tablet, often designated as a sustained-release or Retard formulation. This physical design is a key differentiating feature, as it controls the rate at which Diclofenac is released, ensuring a slow and steady dispersion of the active compound over an extended period.

This special release mechanism distinguishes it from immediate-release forms of Diclofenac, which release their dose quickly. The Retard formulation is engineered to maintain a more stable, therapeutic concentration of the drug in the system for many hours. Such prolonged-release formulations are developed to provide extended effects. This means the sustained action is designed to provide the general benefit of extended relief with a potentially simplified dosing schedule.

What is the General Purpose of This Diclofenac Medicine?

The general purpose of Votrex Retard is to provide sustained relief through its potent anti-inflammatory and analgesic effects. It primarily works by interrupting the internal production of prostaglandins, the signaling chemicals responsible for triggering pain and swelling.

The direct consequence of this systemic action is the reduction of associated swelling, stiffness, and discomfort. By addressing both the pain sensation and the underlying inflammatory process simultaneously, the medicine is utilized to generally ease discomfort related to inflammatory and musculoskeletal issues.

Regulatory References

What side effects are possible with Votrex Retard?

Possible Side Effects and Safety Information

The safety profile for Votrex Retard (Diclofenac sodium) is organized in regulatory documents according to official classifications, grouping potential adverse reactions by the System-Organ Class (SOC) and their reported frequency (Common, Rare, Very Rare).

Common and Rare Adverse Reactions

Adverse reactions classified as Common in official labeling (affecting up to 1 in 10 individuals) frequently involve the Gastrointestinal Disorders system, including symptoms such as nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, and flatulence. Effects on the Nervous System like headache and dizziness are also common. Increased transaminases (liver enzymes) are also frequently reported.

Reactions classified as Rare or Very Rare include more clinically significant events.

Serious Adverse Reactions and Safety Constraints

Official regulatory sources highlight the potential for Serious Adverse Reactions (SARs), which are rare but severe:

Serious Cardiovascular (CV) Thrombotic Events: The potential for events like Myocardial Infarction (MI) and Stroke is documented, and risk may be associated with the duration of use and higher doses.
Serious Gastrointestinal (GI) Adverse Events: Events like bleeding, ulceration, and perforation of the stomach or intestines are highlighted as serious risks that can occur at any time during treatment.
Hepatotoxicity: The label documents the potential for hepatitis and, rarely, fulminant hepatic failure.

Safety constraints necessitate avoiding use in specific situations, such as for pain treatment following Coronary Artery Bypass Graft (CABG) surgery, and in patients with known aspirin-sensitive asthma. Older adults are identified as being at greater risk for serious gastrointestinal events.

Overdose and Emergency Response

Official Documentation on Overdose Manifestations

Overdose with Diclofenac sodium is officially documented to present with a range of symptoms, primarily affecting the gastrointestinal (GI) and central nervous systems (CNS). Common manifestations listed in regulatory information include nausea, vomiting, diarrhea, and stomach pain. CNS effects frequently reported are dizziness, drowsiness, blurred vision, and headache. In rare or severe cases, gastrointestinal hemorrhage (bleeding), acute renal failure, and serious CNS manifestations like seizures and coma may occur. Patients with pre-existing conditions like asthma may experience exacerbated respiratory effects.

Emergency Response and Required Monitoring

Regulatory authorities mandate that immediate medical attention must be sought for any suspected overdosage. Users are instructed to contact emergency services or a Poison Control Center right away. Official documents state that no specific antidote is known for Diclofenac toxicity; therefore, management focuses on supportive and symptomatic treatment, such as activated charcoal and clinical stabilization. Given that Votrex Retard is a prolonged-release formulation, a longer period of hospital monitoring is required to account for the delayed absorption and the potential for a delayed peak in toxicity.

Therapeutic Uses of Votrex Retard

What Votrex Retard Treats: Main Uses and Benefits

Votrex Retard is a prolonged-release medicine commonly applied in clinical settings that involve symptoms related to inflammatory or irritative states where supportive symptom management is appropriate. The oral form may be part of symptomatic management to help relieve symptoms associated with various arthritic conditions.

It is commonly used across conditions characterized by periods of heightened symptoms such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is applied in addressing the symptoms related to physical discomfort, tenderness, and functional strain associated with chronic inflammatory processes. The long-acting formulation may assist with maintaining a sense of stability when symptoms become more noticeable, which contributes to easing the overall symptom load.

It also provides supportive relief for general musculoskeletal disorders and painful episodes where an inflammatory component is present. By addressing symptoms like morning stiffness and swelling, the medication may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Chronic Inflammation
Primary Focus	Sustained management of symptoms related to inflammatory or irritative states (pain, swelling, stiffness).
Key Benefit	Helps ease the overall symptom load for conditions like Arthritis.
Use Context	Applied in daily therapy for chronic joint and musculoskeletal discomfort.

Regulatory References

MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Votrex Retard?

The eligibility for using Votrex Retard (Diclofenac prolonged-release) is strictly governed by a patient's pre-existing conditions, organ function, and age, as defined by regulatory authorities.

Category	Population or Rule	Regulatory Status
Populations for whom use is allowed	Adults	Established use for appropriate labeled indications.
Populations for whom use is contraindicated	History of Hypersensitivity to any NSAID, Severe Hepatic or Renal Failure, Severe Heart Failure (NYHA II–IV), established Ischemic Heart Disease, or active Gastrointestinal Ulceration/Bleeding [1.1, 1.2]. Use is also prohibited in the Last Trimester of Pregnancy (from 30 weeks gestation) and for pre-operative pain in CABG surgery [1.1, 1.2].
Age-related eligibility rules	Children and Adolescents	The prolonged-release formulation is not suitable; safety and efficacy are not established [1.2, 1.3].
Eligibility-related restrictions	Geriatric patients and those with Cardiovascular Risk Factors (e.g., hypertension) should avoid use unless benefits strongly outweigh the risk [1.1, 1.3]. Use during breastfeeding or when attempting to conceive is not recommended [1.3, 3.2].

Connection to the overall eligibility profile: Regulatory documents establish that Votrex Retard is a medicine intended for use only by adults who do not possess a specific set of clinical histories or conditions. Eligibility is fundamentally denied to populations with severe organ dysfunction, established cardiovascular disease, or NSAID-related hypersensitivity, as detailed in official labeling.

What should I know about interactions with other medicines?

Votrex Retard (Diclofenac) is subject to several officially documented interactions that govern co-administration based on regulatory labels. Formal Contraindications prohibit co-use with other NSAIDs (including COX-2 selective inhibitors) and Ketorolac, due to a substantial, documented additive risk of serious gastrointestinal events.

Pharmacodynamic interactions require regulatory caution for combinations that reinforce risks. Co-administering with Anticoagulants (e.g., Warfarin) or SSRIs is linked to an officially increased risk of bleeding. Furthermore, combining Diclofenac with Diuretics or Antihypertensives (ACE inhibitors/ARBs) is documented to increase the risk of acute renal failure (nephrotoxicity). This risk is officially noted to be heightened in the elderly and those with pre-existing renal impairment.

Pharmacokinetic interactions affect drug levels in two ways: Strong inhibitors of CYP2C9 are documented to increase Diclofenac's systemic plasma concentration. Conversely, Diclofenac inhibits the renal clearance of drugs like Lithium and Methotrexate, officially leading to their accumulation and increased exposure. Finally, official regulatory labels state that Bile Acid Sequestrants reduce Diclofenac absorption, requiring the doses to be separated in time (e.g., 4 to 6 hours) to maintain adequate systemic exposure.

Mechanism of Action

How Votrex Retard Works

Votrex Retard's action is governed by two interconnected mechanistic domains, focusing on the peripheral modulation of chemical mediators that regulate specific signaling pathways.

Enzyme Blockade in the Prostanoid Synthesis Pathway

The drug's primary mechanism involves the non-selective inhibition of the Cyclooxygenase (COX) enzymes ( COX-1 and COX-2). By blocking these enzymes, Votrex Retard immediately suppresses the cellular production of prostaglandins and other prostanoids that function as key chemical mediators. This enzymatic blockade is the molecular foundation that establishes the drug’s physiological consequences.

Modulating Peripheral Inflammatory and Pain Signals

Reducing prostaglandin synthesis directly leads to a physiological dampening of the inflammatory cascade and peripheral nociceptor (pain receptor) signaling. This mechanism restricts the tissue-level processes of vasodilation and fluid leakage (edema), while also preventing the chemical hypersensitization of pain nerve endings. These two simultaneous physiological adjustments modulate activity within the targeted pathways.

Dosage and Administration Information

How Votrex Retard is Officially Administered

Votrex Retard is a Diclofenac prolonged-release formulation that must be administered orally. The administration protocol is strictly defined by the tablet's sustained-release design, which controls the rate at which the active substance is dispersed over an extended period. To ensure the intended therapeutic effect and maintain the specialized release mechanism, the tablet must be swallowed whole and intact; it is directed not to chew, crush, or divide the dose. Intake is generally performed with a full glass of water.

Standard Dosing and Frequency

The standard adult dosing regimen is typically 100 mg taken once daily. This once-daily frequency leverages the prolonged-release property of the formulation. For most approved uses, the recommended maximum daily dose for the extended-release tablet is 100 mg. The timing of administration is often flexible, though some protocols suggest taking the dose in the evening to address overnight symptoms, such as morning stiffness. Administration with or without food does not significantly impact the overall absorption of the drug.

Use Over Time and Population Rules

Official guidelines state that the administration of Votrex Retard must follow the principle of using the lowest effective dose for the shortest duration necessary to manage symptoms. While the medicine is approved for long-term use in chronic conditions, this duration principle guides the general administration protocol. For specific populations, caution is advised: the 100 mg prolonged-release tablet is generally not suitable for children and adolescents. For older adults, it is recommended to initiate the treatment at the lowest effective dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Votrex Retard

Evidence for Use in Osteoarthritis

This section will summarize the structure of Randomized Controlled Trials (RCTs) and Systematic Reviews that examined the use of the prolonged-release formulation for symptom management in Osteoarthritis (OA). It will outline the types of outcomes that researchers primarily measured, such as pain severity and functional ability.

The research into the use of Votrex Retard for the symptomatic management of Osteoarthritis primarily centers on Randomized Controlled Trials (RCTs). These studies were designed to evaluate the use of the medicine compared to a non-active treatment (placebo) or against other similar medicines. Researchers have specifically focused on outcomes related to physical discomfort. Studies also examined symptom intensity and measures related to functional stability using validated indices, which reflect daily functioning or activity level.

Studies exploring short-term symptom changes, often lasting just a few weeks, provided the initial data. These studies monitored measurements of pain severity and joint stiffness over the observed periods. Some studies comparing different forms of diclofenac described patterns observed in the trials; however, regulatory reviews have noted that findings on pain and function metrics across the broad spectrum of diclofenac research were sometimes mixed or varied.

Evidence for Use in Rheumatoid Arthritis

Here, the focus will be on the clinical trials and regulatory documents that established the role of this medicine for long-term symptomatic management in Rheumatoid Arthritis (RA). The summary will describe the primary endpoints used in these studies for chronic inflammatory signs.

The prolonged-release medicine was studied in research contexts involving fluctuating or unstable symptoms, such as Rheumatoid Arthritis. Research examined outcomes linked to inflammatory or irritative states and the sustained relief of general signs and symptoms over time. The findings describe group patterns observed in long-term observational settings evaluating daily-life functioning of adult patients.

Studies contributed to understanding symptom patterns over defined time intervals, providing data used to support the medicine's regulatory designation for long-term symptomatic treatment. The medicine was studied in research exploring its use in conditions characterized by fluctuating or episodic manifestations. Findings described patterns observed during the study period, contributing to the understanding of the medicine's role in the long-term management of chronic joint issues.

Evidence for Use in Ankylosing Spondylitis

This part will review the clinical trial designs that explored the management of chronic pain and inflammation related to Ankylosing Spondylitis (AS). It will include a description of studies that evaluated disease activity using validated functional scales and those that tracked radiographic progression.

Votrex Retard was evaluated in research contexts involving fluctuating or unstable symptoms, specifically for Ankylosing Spondylitis. Studies explored the management of chronic pain and functional imbalance, using standardized scales to monitor physiological strain. Research examined different strategies, such as continuous daily use versus on-demand use during phases of heightened symptom activity.

Studies monitored how symptoms evolved in the observed populations over intermediate to long-term follow-up durations, sometimes lasting for two years. Research describes the use of this medicine in conditions marked by functional limitations. The available evidence contributes to understanding symptom patterns in conditions presenting with cycles of stability and flare-ups.

Long-Term Studies and Extended Follow-up

This section will describe the nature of the research that extends beyond short-term treatment, focusing on observational cohorts and long-term regulatory follow-up. It will summarize what is known about the observation periods and the durability of the research base over many months of use.

Research exploring short-term symptom changes in RCTs often uses follow-up durations that are limited (e.g., 2–4 weeks). To address this, the evidence landscape includes long-term observational studies and data from extended regulatory follow-up, sometimes monitoring use for a year or more. These studies monitor responses over defined time intervals.

These extended studies are primarily applied in observational settings evaluating daily-life functioning. They help show what has been observed so far in real-world use for conditions involving periods of heightened symptoms. Findings describe group patterns related to long-term usage, rather than providing individual predictions about sustained symptom relief.

Research in Special and Sub-Populations

This part will outline which patient groups, such as older adults and specific comorbidity cohorts, have been included in the research base for this medicine. It will describe the types of studies available for these groups, acknowledging where the evidence base is primarily focused.

Votrex Retard was studied for its relevance in trials assessing symptom patterns in various groups, including a specific focus on older adult patients with Osteoarthritis. The research has explored how symptoms change over time in cohorts where this condition is most prevalent.

For populations defined by co-occurring health issues (comorbidities), such as cardiovascular concerns, studies have primarily been conducted in large-scale, long-term comparator trials involving multiple NSAIDs. These studies provide evidence derived from settings with varying symptom burdens.

What is Still Uncertain in the Research Landscape

This final section will synthesize the evidence gaps and study limitations noted in the scientific literature and regulatory reviews. It will clarify the main areas where research remains inconsistent, requires more data, or relies on the general evidence for the NSAID class.

Despite the foundational research, certain areas of the evidence base are subject to ongoing discussion. The follow-up durations were limited for many of the primary, controlled efficacy assessments, which restricts the insight into long-term outcomes. Furthermore, certain structural outcomes, particularly for Ankylosing Spondylitis, were associated with mixed findings across studies.

This means that while studies provide context for symptom management, the existing data provides limited insight into the medicine's impact on certain structural outcomes. Overall, evidence highlights what is known, but also clarifies that research is ongoing and data for certain groups remain insufficient. Study results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Votrex Retard (FAQ)

Q: What is Votrex Retard, and what is it used for?

Votrex Retard is the brand name for a medicine containing the active ingredient diclofenac sodium. It belongs to a group of medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

It is used to relieve pain and inflammation (swelling) associated with:

Joint pain and conditions, such as osteoarthritis and rheumatoid arthritis.
Muscle pain or ligament injuries.
Pain following surgery.

Q: How does Votrex Retard work to relieve pain and swelling?

Votrex Retard (diclofenac) works by blocking the production of certain natural substances in the body called prostaglandins. Prostaglandins are key chemicals that the body releases in response to injury or certain diseases. They cause pain, swelling, and inflammation.

By reducing the level of these prostaglandins, Votrex Retard helps to reduce both the painful feeling and the associated inflammation at the site of the injury or disease.

Q: What is the difference between Votrex and Votrex Retard?

Both Votrex and Votrex Retard contain the active ingredient diclofenac.

The main difference is in how the medicine is released into the body:

Votrex (standard-release): The medicine is released relatively quickly. This provides fast relief but requires multiple doses throughout the day.
Votrex Retard (slow- or modified-release): The medicine is released slowly and steadily over many hours. This allows for a longer duration of effect, typically permitting dosing once or twice a day. This slower release is often preferred for chronic conditions needing constant pain control.

Always take the specific formulation prescribed by your doctor.

Q: Can Votrex Retard cause stomach problems?

Yes, Votrex Retard, like other NSAIDs, can irritate the stomach lining. This can potentially lead to stomach upset, nausea, or, less commonly but more seriously, stomach ulcers or bleeding.

To help minimize this risk:

Always take the medicine exactly as prescribed, generally with food or milk.
Your doctor may prescribe a second medication, such as a proton pump inhibitor, to protect your stomach, especially if you are taking Votrex Retard for a long time or have a history of stomach problems.
Tell your doctor immediately if you experience persistent stomach pain or black/tarry stools.

Q: How long does it take for Votrex Retard to start working?

Because Votrex Retard is a slow-release formulation, it does not provide the immediate relief of a standard tablet.

Initial pain relief may be noticeable within a few hours of the first dose.
However, it may take several days or up to one to two weeks of continuous use for the full anti-inflammatory effects to become apparent, especially when treating chronic conditions like arthritis.

Q: Who should not take Votrex Retard?

Votrex Retard is not suitable for everyone. Do not take this medicine if you have any of the following conditions:

A known allergy to diclofenac, aspirin, or any other NSAID.
A current or recent history of stomach ulcers, bleeding, or perforation in the stomach or intestines.
Severe heart failure or established heart disease (e.g., prior heart attack).
Severe kidney or liver problems.
The last three months of pregnancy.

Always inform your doctor of your complete medical history before starting Votrex Retard.

How should Votrex Retard be stored and disposed of?

How to Store and Dispose of Votrex Retard?

Storage Requirement	Official Condition
Temperature	Store at controlled room temperature, typically between 20 C and 25 C; do not store above 30 C.
Environmental	Must be protected from light and moisture and should be preserved in its original, well-closed container.
Handling	The product must not be frozen.

The official storage conditions are mandatory to maintain the integrity of the prolonged-release tablet and the Diclofenac active substance. It is required to keep Votrex Retard out of the sight and reach of children at all times. Regarding disposal, unused or expired medicine must not be thrown into household waste or wastewater; instead, it should be discarded according to local regulatory requirements for pharmaceutical returns.

Votrex Retard